DCM
GPCR icon

Driehaus Capital Management’s Structure Therapeutics GPCR Stock Holding History

Driehaus Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76M Sell
1,577,356
-65,088
-4% -$4.45M 0.56% 43
2025
Q4 		$114M Buy
1,642,444
+768,940
+88% +$31.4M 0.78% 27
2025
Q3 		$24.5M Buy
873,504
+200,712
+30% +$4M 0.18% 186
2025
Q2 		$14M Sell
672,792
-599,951
-47% -$13.2M 0.11% 220
2025
Q1 		$22M Sell
1,272,743
-784,667
-38% -$19.2M 0.21% 144
2024
Q4 		$55.8M Sell
2,057,410
-469,020
-19% -$16.6M 0.46% 75
2024
Q3 		$111M Sell
2,526,430
-50,706
-2% -$1.96M 0.95% 16
2024
Q2 		$101M Buy
2,577,136
+86,833
+3% +$3.57M 0.98% 16
2024
Q1 		$107M Sell
2,490,303
-108,776
-4% -$4.59M 1.06% 15
2023
Q4 		$106M Buy
2,599,079
+210,203
+9% +$12M 1.28% 8
2023
Q3 		$120M Buy
2,388,876
+1,252,940
+110% +$40.4M 1.57% 7
2023
Q2 		$47.2M Buy
1,135,936
+195,708
+21% +$5.48M 0.6% 42
2023
Q1 		$22.4M Buy
+940,228
New +$22.1M 0.31% 103

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Driehaus Capital Management's GPCR Position: Q1 2026 in Review

Driehaus Capital Management reduced its Structure Therapeutics (GPCR) stake by 4% in Q1 2026, selling an estimated $4.45M and leaving 1,577,356 shares worth $76M. The position accounts for 0.56% of the portfolio, ranked #43.

Driehaus Capital Management first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $120M in Q3 2023. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Driehaus Capital Management held 1,577,356 shares of Structure Therapeutics worth $76M as of Q1 2026.
  • Driehaus Capital Management sold 65,088 Structure Therapeutics shares in Q1 2026, an estimated $4.45M.
  • Structure Therapeutics made up 0.56% of Driehaus Capital Management's portfolio in Q1 2026, its #43 holding.
  • Driehaus Capital Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Driehaus Capital Management's Structure Therapeutics position peaked at $120M in Q3 2023.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.